Skip to main content

Peer Review reports

From: A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

Original Submission
13 Aug 2021 Submitted Original manuscript
18 Oct 2021 Reviewed Reviewer Report
23 Oct 2021 Reviewed Reviewer Report
10 Nov 2021 Author responded Author comments - Soo Jin Park
Resubmission - Version 2
10 Nov 2021 Submitted Manuscript version 2
19 Dec 2021 Author responded Author comments - Soo Jin Park
Resubmission - Version 3
19 Dec 2021 Submitted Manuscript version 3
Publishing
22 Dec 2021 Editorially accepted
3 Jan 2022 Article published 10.1186/s12885-021-09138-z

You can find further information about peer review here.

Back to article page